Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Metformin/Vildagliptin vs Galvumet in Healthy Volunteers
NCT06073600Phase 1Completed
- Sponsor
- Research Laboratory of Clinical and Experimental Pharmacology
- Start
- May 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vildagliptin + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Research Laboratory of Clinical and Experimental Pharmacology. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last measurable concentration and 1 more. Started May 2022; status: completed.
02
Drugs
vildagliptin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06073600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06073600.